AnaptysBio (NASDAQ:ANAB) Now Covered by Analysts at Wolfe Research

Wolfe Research began coverage on shares of AnaptysBio (NASDAQ:ANAB) in a research note issued to investors on Tuesday, MarketBeat reports. The firm issued an outperform rating and a $25.00 price target on the biotechnology company’s stock.

Other research analysts have also issued reports about the company. UBS Group upped their target price on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. dropped their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. HC Wainwright reiterated a “neutral” rating and issued a $19.00 target price on shares of AnaptysBio in a research note on Tuesday. Truist Financial dropped their price target on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Finally, Guggenheim reduced their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $40.08.

AnaptysBio Stock Performance

ANAB stock opened at $16.51 on Tuesday. The stock has a market cap of $502.40 million and a P/E ratio of -2.72. The firm has a 50 day simple moving average of $17.23 and a 200 day simple moving average of $26.89. AnaptysBio has a 52 week low of $12.51 and a 52 week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. Sell-side analysts predict that AnaptysBio will post -6.08 EPS for the current year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the purchase, the director now directly owns 7,880,094 shares in the company, valued at $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 33.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ANAB. Values First Advisors Inc. bought a new position in AnaptysBio during the third quarter worth $49,000. nVerses Capital LLC grew its position in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 644 shares during the last quarter. Point72 DIFC Ltd increased its holdings in shares of AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 5,342 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of AnaptysBio by 35.0% in the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 4,231 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.